Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

mu sars cov 2 variant highly resistant to neutralization by convalescent and vaccinated sera

Sumary of Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera:

  • 1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.
  • “Since breakthrough infection by newly emerging variants is a major concern during the current COVID-19 pandemic, we believe that our findings are of significant public health interest,” writes the team from the University of Tokyo, Kyoto University, Chiba University, and Tokai University in Kanagawa.
  • ” A pre-print version of the research paper is available on the bioRxiv* server, while the article undergoes peer review.
  • More about the variants that have emerged so far Since the COVID-19 outbreak first began in late December 2019, the evolution of the causative agent SARS-CoV-2 has led to the emergence of four variants of concern including the alpha (B.
  • Newly emerged variants need to be carefully assessed The WHO defines “comparative assessment of virus characteristics and public health risks” as the primary action to take in response to the emergence of new SARS-CoV-2 variants.
  • The resistance to humoral immunity elicited by natural SARS-CoV-2 infection or vaccination may enable significant viral transmission in populations that had otherwise been considered protected.
  • The resistance that emergent variants have so far exhibited can be attributed to several mutations that have arisen in the viral spike protein – the primary structure involved in mediating the infection of host cells.
  • New COVID-19 cases per day (black line, left y-axis) and percentage of different SARS-CoV-2 variants spreading in Colombia (right y-axis) are shown.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close